Mitomycin-C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: Cumulative toxicity of an old drug in a new era

Roland El-Ghazal; Nikolai Podoltsev; Peter Marks; Edward Chu; Muhammad Wasif Saif

doi:10.1016/j.clcc.2011.03.012

Mitomycin-C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: Cumulative toxicity of an old drug in a new era

Roland El-Ghazal, Nikolai Podoltsev, Peter Marks, Edward Chu, Muhammad Wasif Saif

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Mitomycin-C (MMC) is a first-line therapy for anal squamous cell carcinoma (ASCC), and it continues to be used for several other indications. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are serious complications of MMC therapy. Herein, we describe a 73-year-old woman with recurrent ASCC treated with MMC who developed chronic microangiopathic hemolytic anemia (MAHA) and thrombocytopenia after receiving a cumulative dose of 50 mg/m2. These hematologic adverse events persisted for 9 months and resolved after discontinuation of chemotherapy followed by multiple courses of oral corticosteroids. This report describes an atypically chronic and mild form of secondary TTP/HUS and discusses the possible role of corticosteroids in its management.

Original language	English (US)
Pages (from-to)	142-145
Number of pages	4
Journal	Clinical colorectal cancer
Volume	10
Issue number	2
DOIs	https://doi.org/10.1016/j.clcc.2011.03.012
State	Published - Jun 2011
Externally published	Yes

Keywords

Anal squamous cell carcinoma
Anemia
Drug toxicity
Prednisone
Thrombocytopenia

ASJC Scopus subject areas

Oncology
Gastroenterology

Access to Document

10.1016/j.clcc.2011.03.012

Cite this

@article{4096dbbc9865402abb9152768ca1d95d,

title = "Mitomycin-C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: Cumulative toxicity of an old drug in a new era",

abstract = "Mitomycin-C (MMC) is a first-line therapy for anal squamous cell carcinoma (ASCC), and it continues to be used for several other indications. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are serious complications of MMC therapy. Herein, we describe a 73-year-old woman with recurrent ASCC treated with MMC who developed chronic microangiopathic hemolytic anemia (MAHA) and thrombocytopenia after receiving a cumulative dose of 50 mg/m2. These hematologic adverse events persisted for 9 months and resolved after discontinuation of chemotherapy followed by multiple courses of oral corticosteroids. This report describes an atypically chronic and mild form of secondary TTP/HUS and discusses the possible role of corticosteroids in its management.",

keywords = "Anal squamous cell carcinoma, Anemia, Drug toxicity, Prednisone, Thrombocytopenia",

author = "Roland El-Ghazal and Nikolai Podoltsev and Peter Marks and Edward Chu and {Wasif Saif}, Muhammad",

year = "2011",

month = jun,

doi = "10.1016/j.clcc.2011.03.012",

language = "English (US)",

volume = "10",

pages = "142--145",

journal = "Clinical colorectal cancer",

issn = "1533-0028",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Mitomycin-C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome

T2 - Cumulative toxicity of an old drug in a new era

AU - El-Ghazal, Roland

AU - Podoltsev, Nikolai

AU - Marks, Peter

AU - Chu, Edward

AU - Wasif Saif, Muhammad

PY - 2011/6

Y1 - 2011/6

N2 - Mitomycin-C (MMC) is a first-line therapy for anal squamous cell carcinoma (ASCC), and it continues to be used for several other indications. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are serious complications of MMC therapy. Herein, we describe a 73-year-old woman with recurrent ASCC treated with MMC who developed chronic microangiopathic hemolytic anemia (MAHA) and thrombocytopenia after receiving a cumulative dose of 50 mg/m2. These hematologic adverse events persisted for 9 months and resolved after discontinuation of chemotherapy followed by multiple courses of oral corticosteroids. This report describes an atypically chronic and mild form of secondary TTP/HUS and discusses the possible role of corticosteroids in its management.

AB - Mitomycin-C (MMC) is a first-line therapy for anal squamous cell carcinoma (ASCC), and it continues to be used for several other indications. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are serious complications of MMC therapy. Herein, we describe a 73-year-old woman with recurrent ASCC treated with MMC who developed chronic microangiopathic hemolytic anemia (MAHA) and thrombocytopenia after receiving a cumulative dose of 50 mg/m2. These hematologic adverse events persisted for 9 months and resolved after discontinuation of chemotherapy followed by multiple courses of oral corticosteroids. This report describes an atypically chronic and mild form of secondary TTP/HUS and discusses the possible role of corticosteroids in its management.

KW - Anal squamous cell carcinoma

KW - Anemia

KW - Drug toxicity

KW - Prednisone

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=79959340173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959340173&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2011.03.012

DO - 10.1016/j.clcc.2011.03.012

M3 - Article

C2 - 21859568

AN - SCOPUS:79959340173

SN - 1533-0028

VL - 10

SP - 142

EP - 145

JO - Clinical colorectal cancer

JF - Clinical colorectal cancer

IS - 2

ER -

Mitomycin-C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: Cumulative toxicity of an old drug in a new era

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this